Results 151 to 160 of about 8,460,931 (324)

Frequency and clinical features of Lewy body dementia in Italian memory clinics

, 2009
Background: The latest developments in Lewy Body Dementia (DLB) raise some controversies on clinical features, neuroimaging and therapy. The aim of our study is to determine clinical, neuropsychological, neuroimaging and EEG profile of DLB through ...
F. Olivotto, E.A. Scarpini, Dementias Associated to Parkinsonism, C. Bascelli, E. Schiatti, F. Mantovani, M. Zuffi, E. Farina, M. Alberoni, C. Vismara, P. Caffarra, R. Regazzoni, M. Bellotti, M. Franceschi, G. Messa, V. Fetoni, A. Barbieri, I. Restelli, I. Appollonio, M. Donato, F. Baglio, R. Nemni, S. Castiglioni, Italian Group for Lewy Body Dementia, G. Magnani, V. Isella, A. Cheldi, M. Falautano   +27 more
core   +2 more sources

The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.

Journal of Neurology Neurosurgery & Psychiatry, 1988
W. Gibb, A. J. Lees
semanticscholar   +1 more source

Lower Urinary Tract Symptoms as Diagnostic Clues in Parkinsonism: A Practical Framework for Neurologists

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Lower urinary tract symptoms (LUTS) are among the most prevalent nonmotor complaints across the parkinsonian spectrum, yet they remain underutilized as diagnostic and management signals in neurology practice. Although prior reviews have characterized disease‐specific patterns of urinary dysfunction, and recent guidelines address ...
Saar Anis, Omer Anis, Abhishek Lenka, Junaid H. Siddiqui   +3 more
wiley   +1 more source

Should Paratonia Be Considered a Movement Disorder? Implications for Clinical Management

Movement Disorders Clinical Practice, EarlyView.
Abstract Paratonia is an involuntary and variable resistance to passive movement that emerges with cognitive decline in dementias of different etiologies, with prevalence approaching 90% to 100% in end‐stage disease. It is common in Parkinson disease and the atypical parkinsonisms.
Galit Kleiner, Christos Ganos, Anthony E. Lang   +2 more
wiley   +1 more source

Glucocerebrosidase mutations in diffuse Lewy body disease

, 2011
Clinicogenetic and pathological studies have shown that mutations of the glucocerebrosidase gene (GBA) are a risk factor for Parkinson's disease and Lewy body disorders.
Alex Rajput, Cobb, Stephanie A, Dickson, Dennis W., Zbigniew K. Wszolek, Owen A. Ross, David M.A. Mann, Mash, Deborah C., Ross, Owen A., Stephanie A. Cobb, Snowden, Julie, Mann, David M.A, Matthew J. Farrer, Wszolek, Zbigniew K., Rajesh Pahwa, Julie Snowden, Farrer, Matthew J., David Neary, Kachergus, Jennifer M, Farrer, Matthew J, Neary, David, Vilariño-Güell, Carles, Papapetropoulos, Spiridon, Christopher A. Robinson, Richardson, Anna M.T, Carles Vilariño-Güell, Lyons, Kelly E, Lyons, Kelly E., Wszolek, Zbigniew K, Spiridon Papapetropoulos, Dennis W. Dickson, Ross, Owen A, Nishioka, Kenya, Deborah C. Mash, Jennifer M. Kachergus, Cobb, Stephanie A., Robinson, Christopher A, Mash, Deborah C, Mann, David M A, Pahwa, Rajesh, Robinson, Christopher A., Richardson, Anna M T, Rajput, Alex, Kenya Nishioka, Dickson, Dennis W, Kachergus, Jennifer M., Anna M.T. Richardson, Kelly E. Lyons   +46 more
core   +1 more source

The GBA1 p.E427K (p.E388K) Variant Is a Risk Factor for Synucleinopathies: A Meta‐Analysis

Movement Disorders, EarlyView.
Abstract Background Variants in GBA1 are important genetic risk factors for synucleinopathies, including Parkinson's disease (PD). Although several GBA1 variants are established risk or severity modifiers, the role of the p.E427K variant remains unclear.
Leah V. Chifamba, Sitki Cem Parlar, Emma N. Somerville, Lang Liu, Eric Yu, Farnaz Asayesh, Jamil Ahmad, Meron Teferra, Jennifer A. Ruskey, Cheryl Waters, Oury Monchi, Yves Dauvilliers, Nicolas Dupré, Alla Timofeeva, Anton Emelyanov, Sofya Pchelina, Irina Miliukhina, Lior Greenbaum, Sharon Hassin‐Baer, Orly Goldstein, Mandy Radefeldt, Peter Bauer, Christian Beetz, Allison A. Dilliott, James C. Beck, Konstantin Senkevich, ROPAD Study Group, The Parkinson's Foundation PD GENEration Study, Christine Klein, Roy N. Alcalay, Ziv Gan‐Or   +30 more
wiley   +1 more source

The Lewy Body Dementias

Lewy body dementia (LBD) is the second most common form of neurocognitive disorder after Alzheimer’s disease and covers two related diagnoses: dementia with Lewy Bodies and Parkinson’s disease dementia.
Bras, Jose Tomas, Goate, Alison M., Galvin, James E.   +2 more
core   +1 more source

Pathogenesis of Lewy Body Dementia

, 2017
This chapter discusses the Pathogenesis of Lew Body Dementia. The Lewy body dementias (LBDs) are a spectrum of dementing neurodegenerative disorders underpinned by the pathological accumulation of α- synuclein protein in both intraneuronal inclusions ...
Jagan A. Pillai, James B. Leverenz
core   +1 more source

Plasma p‐tau217 Versus p‐tau181 in Parkinson's Disease: Differential Associations with Alzheimer's Disease‐Related Neurostructural Changes and Cognitive Function

Movement Disorders, EarlyView.
Abstract Background Plasma phosphorylated‐tau at threonine‐217 (p‐tau217) and threonine‐181 (p‐tau181) are scalable, minimally invasive biomarkers of Alzheimer's disease (AD) pathology. In Parkinson's disease (PD), AD co‐pathology may contribute to its clinical heterogeneity.
Eleonora Fiorenzato, Simone Cauzzo, Giulia Musso, Roberta Biundo, Chiara Ceolin, Chiara Cosma, Carmelo Alessandro Fogliano, Wassilios G. Meissner, Valentina Misenti, Stefania Moz, Maria Laura Nasi, Francesca Vianello, Renzo Manara, Martina Montagnana, Giuseppe Sergi, Angelo Antonini, on behalf of the OPA Working Group   +16 more
wiley   +1 more source

Getting to the heart of Lewy body disease

The Journal of Clinical Investigation
Early identification of neurodegenerative diseases before extensive neuronal loss or disabling symptoms have occurred is imperative for effective use of disease-modifying therapies.
Anna E. Goodheart, Craig Blackstone
doaj   +1 more source